BioSpace News Archive

Mission Therapeutics, a drug discovery and development company focused on protein homeostasis by selectively inhibiting deubiquitylating enzymes, announced it has been granted approval to take its lead USP30 DUB inhibitor, MTX652, into clinical study.

Airway Therapeutics, Inc. announced dosing of the first patient on March 28, 2022 in the Phase 1b randomized trial of AT-100 for preventative use in very preterm infants at risk for bronchopulmonary dysplasia.

Hummingbird Diagnostics GmbH announced the publication of a study in the journal npj Precision Oncology that describes the discovery and validation of miRisk, a first-of-its-kind microRNA biomarker signature that offers the prospect of a blood-based companion diagnostic for immunotherapy in advanced non-small cell lung cancer.

IAMA Therapeutics announced the formation of a Scientific Advisory Board consisting of world-renowned experts in computational chemistry, protein drug design, and neurodevelopmental disorders.

In its latest Medical Device Tech Watch, Vizient, Inc. provides updated trends in patient quality outcomes for transcatheter valve replacement, including insights for complications and physician expertise.

Clovis Oncology, Inc. announced positive top-line data from the monotherapy arm of the ATHENA trial demonstrating that Rubraca as maintenance treatment successfully achieved the primary endpoint of significantly improved investigator-assessed progression-free survival compared with placebo.

Nuvalent, Inc., a clinical stage biopharmaceutical company creating precisely targeted therapies for clinically proven kinase targets in cancer, announced the appointment of Anna Protopapas, President and Chief Executive Officer of Mersana Therapeutics, as Chair of its Board of Directors.

BD, a leading global medical technology company, announced that Alberto Mas has informed the company of his intent to retire from BD, effective at the end of the company’s fiscal year on Sept. 30, 2022.

BioNTech SE announced that it has entered into a share repurchase program, pursuant to which the Company may purchase American depositary shares in the amount of up to $1.5 billion over the next two years.

PDS Biotechnology Corporation provided a business update and announced its financial results for the year ended December 31, 2021.